TWI848030B - Ｃｄ７０組合治療 - Google Patents

Ｃｄ７０組合治療 Download PDF

Info

Publication number
TWI848030B
TWI848030B TW108146057A TW108146057A TWI848030B TW I848030 B TWI848030 B TW I848030B TW 108146057 A TW108146057 A TW 108146057A TW 108146057 A TW108146057 A TW 108146057A TW I848030 B TWI848030 B TW I848030B
Authority
TW
Taiwan
Prior art keywords
combination
antibody
antigen
binding fragment
bcl
Prior art date
Application number
TW108146057A
Other languages
English (en)
Chinese (zh)
Other versions
TW202038958A (zh
Inventor
范 盧克 羅姆
德 漢斯 哈德
尼古拉斯 勒平
薩姆森 馮
卡斯滕 里瑟
阿德里安 奧克森貝恩
Original Assignee
比利時商阿根思公司
伯爾尼大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1820582.3A external-priority patent/GB201820582D0/en
Priority claimed from GBGB1911007.1A external-priority patent/GB201911007D0/en
Priority claimed from GBGB1917701.3A external-priority patent/GB201917701D0/en
Application filed by 比利時商阿根思公司, 伯爾尼大學 filed Critical 比利時商阿根思公司
Publication of TW202038958A publication Critical patent/TW202038958A/zh
Application granted granted Critical
Publication of TWI848030B publication Critical patent/TWI848030B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW108146057A 2018-12-18 2019-12-16 Ｃｄ７０組合治療 TWI848030B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB1820582.3 2018-12-18
GBGB1820582.3A GB201820582D0 (en) 2018-12-18 2018-12-18 CD70 combination therapy
GBGB1911007.1A GB201911007D0 (en) 2019-08-01 2019-08-01 CD70 combination therapy
GB1911007.1 2019-08-01
GB1917701.3 2019-12-04
GBGB1917701.3A GB201917701D0 (en) 2019-12-04 2019-12-04 CD70 Combination therapy

Publications (2)

Publication Number Publication Date
TW202038958A TW202038958A (zh) 2020-11-01
TWI848030B true TWI848030B (zh) 2024-07-11

Family

ID=69104399

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108146057A TWI848030B (zh) 2018-12-18 2019-12-16 Ｃｄ７０組合治療

Country Status (21)

Country Link
US (3) US11712468B2 (cg-RX-API-DMAC10.html)
EP (2) EP3890740B1 (cg-RX-API-DMAC10.html)
JP (2) JP7565921B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210106428A (cg-RX-API-DMAC10.html)
CN (2) CN115920034B (cg-RX-API-DMAC10.html)
AU (2) AU2019409936B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021011684A2 (cg-RX-API-DMAC10.html)
DK (1) DK3890740T3 (cg-RX-API-DMAC10.html)
ES (1) ES2941638T3 (cg-RX-API-DMAC10.html)
FI (1) FI3890740T3 (cg-RX-API-DMAC10.html)
HU (1) HUE061710T2 (cg-RX-API-DMAC10.html)
IL (1) IL284015B2 (cg-RX-API-DMAC10.html)
LT (1) LT3890740T (cg-RX-API-DMAC10.html)
MX (1) MX2021007350A (cg-RX-API-DMAC10.html)
PL (1) PL3890740T3 (cg-RX-API-DMAC10.html)
PT (1) PT3890740T (cg-RX-API-DMAC10.html)
SG (1) SG11202105197UA (cg-RX-API-DMAC10.html)
TW (1) TWI848030B (cg-RX-API-DMAC10.html)
UY (1) UY38511A (cg-RX-API-DMAC10.html)
WO (1) WO2020127503A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202103044B (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
WO2020257671A1 (en) * 2019-06-20 2020-12-24 Celgene Corporation Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
TWI877278B (zh) * 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
MX2023002318A (es) * 2020-08-29 2023-05-19 argenx BV Metodo de tratamiento de pacientes con sensibilidad reducida a un inhibidor de bcl-2.
BR112023017371A2 (pt) * 2021-03-19 2023-10-03 Eil Therapeutics Inc Compostos que têm ((3-nitrofenil)sulfonil)acetamida como inibidores de bcl-2
US20240342157A1 (en) * 2021-07-21 2024-10-17 Emory University Bak activators, pharmaceutical compositions, and uses in treating cancer
WO2023031403A1 (en) * 2021-09-02 2023-03-09 F. Hoffmann-La Roche Ag Antibodies for the treatment of aml
US20240426824A1 (en) * 2021-11-03 2024-12-26 Stefan E. HUBNER Methods relating to treatment of acute myeloid leukemia
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
CN114949230B (zh) * 2022-06-13 2024-12-06 厦门大学附属第一医院 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用
CN117771177A (zh) * 2023-08-02 2024-03-29 首都医科大学附属北京儿童医院 维奈克拉自微乳化释药系统及其制备方法和应用
WO2025181039A1 (en) * 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager
WO2025212259A1 (en) * 2024-04-02 2025-10-09 Board Of Regents, The University Of Texas System Methods for prognosing and treating acute myeloid leukemia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017160954A1 (en) * 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
US20030148321A1 (en) 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
EP1470247A2 (en) 2001-11-05 2004-10-27 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
NZ533240A (en) 2001-11-27 2007-12-21 Oxford Glycosciences Uk Ltd Use of polypeptide for the treatment of epithelial-derived cancer
US7261892B2 (en) 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
WO2006044643A2 (en) 2004-10-15 2006-04-27 Seattle Genetics, Inc. Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006113747A2 (en) 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US8067546B2 (en) 2005-04-19 2011-11-29 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
US20080280297A1 (en) 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
EP1934261B1 (en) 2005-09-26 2014-10-29 Medarex, L.L.C. Human monoclonal antibodies to cd70
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
CN101489697B (zh) 2006-07-24 2011-06-01 千田建设股份有限公司 金属线材除锈的方法及其装置
PL2099823T5 (pl) 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
KR100807069B1 (ko) 2007-09-21 2008-02-25 고려대학교 산학협력단 암 치료용 의약 조성물
AU2008324203A1 (en) 2007-11-05 2009-05-14 Novartis Ag Methods and compositions for measuring Wnt activation and for treating Wnt-related cancers
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010014948A1 (en) 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
WO2010019921A2 (en) 2008-08-15 2010-02-18 The Regents Of The University Of California Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
ES2835553T3 (es) 2009-08-10 2021-06-22 Biosplice Therapeutics Inc Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos
WO2011035433A1 (en) 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
AU2010339359A1 (en) 2009-12-29 2012-07-26 Kyowa Hakko Kirin Co., Ltd. Anti-CD27 antibody
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
JP5940093B2 (ja) 2011-01-19 2016-06-29 カンタージア アクチエボラーグ 抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用
BR112013021562B1 (pt) 2011-03-16 2023-01-10 Argenx Bvba Anticorpos para cd70
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
AP2014007588A0 (en) 2011-09-22 2014-04-30 Amgen Inc CD27L antigen binding proteins
WO2013093508A2 (en) 2011-12-22 2013-06-27 Oslo University Hospital Hf Wnt pathway inhibitors
JO3787B1 (ar) 2012-03-15 2021-01-31 Janssen Biotech Inc أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها
US20150086521A1 (en) 2012-03-21 2015-03-26 Erytech Pharma Medicament for the Treatment of Acute Myeloid Leukemia (AML)
US9801851B2 (en) 2012-05-23 2017-10-31 St. Jude Children's Research Hospital Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias
RU2627712C2 (ru) 2012-06-15 2017-08-10 Кьюрдженикс Инк. Соединение как ингибитор передачи сигналов wnt, его композиции и применение
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
US20150315279A1 (en) 2012-12-21 2015-11-05 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
DK2956173T3 (en) 2013-02-14 2017-07-17 Bristol Myers Squibb Co TUBULYSIS RELATIONSHIPS, METHODS OF PRODUCING AND USING THEREOF
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
WO2017044752A1 (en) 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
BR112018008882A8 (pt) * 2015-11-03 2019-02-26 Univ Texas método para tratar um distúrbio proliferativo e produto farmacêutico
WO2017156398A1 (en) 2016-03-10 2017-09-14 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
CN109563096A (zh) 2016-06-09 2019-04-02 雷迪博士实验室有限公司 固体形式的维奈托克和用于制备维奈托克的方法
EP3481397A1 (en) 2016-07-06 2019-05-15 Concert Pharmaceuticals Inc. Deuterated venetoclax
CN107648185A (zh) 2016-07-25 2018-02-02 常州爱诺新睿医药技术有限公司 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法
US20190177317A1 (en) 2016-08-12 2019-06-13 Mylan Laboratories Limited Process for the preparation of venetoclax
WO2018069941A2 (en) 2016-10-14 2018-04-19 Mylan Laboratories Limited Polymorphic forms of venetoclax
EP3333167A1 (en) 2016-12-09 2018-06-13 LEK Pharmaceuticals d.d. Solid forms of venetoclax
CZ201769A3 (cs) 2017-02-06 2018-08-15 Zentiva, K.S. Pevné formy venetoclaxu
WO2018157803A1 (zh) 2017-02-28 2018-09-07 苏州科睿思制药有限公司 维奈妥拉的晶型及其制备方法
WO2018167652A1 (en) 2017-03-13 2018-09-20 Laurus Labs Limited Process for preparation of amorphous form of venetoclax
CN107089981A (zh) 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
GB2567613A (en) 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
GB201800649D0 (en) * 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017160954A1 (en) * 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors

Also Published As

Publication number Publication date
PT3890740T (pt) 2023-05-15
WO2020127503A1 (en) 2020-06-25
AU2019409936A1 (en) 2021-05-27
CA3117282A1 (en) 2020-06-25
US20250152707A1 (en) 2025-05-15
HUE061710T2 (hu) 2023-08-28
US11712468B2 (en) 2023-08-01
JP2022515077A (ja) 2022-02-17
ES2941638T3 (es) 2023-05-24
CN115920034A (zh) 2023-04-07
PL3890740T3 (pl) 2023-07-24
CN113226317B (zh) 2022-08-16
MX2021007350A (es) 2021-09-21
AU2019409936B2 (en) 2025-09-11
FI3890740T3 (fi) 2023-05-24
JP2025000862A (ja) 2025-01-07
US20200222532A1 (en) 2020-07-16
AU2025259981A1 (en) 2025-11-20
SG11202105197UA (en) 2021-07-29
TW202038958A (zh) 2020-11-01
BR112021011684A2 (pt) 2021-11-30
EP3890740A1 (en) 2021-10-13
US20240033353A1 (en) 2024-02-01
IL284015B2 (en) 2024-10-01
KR20210106428A (ko) 2021-08-30
CN113226317A (zh) 2021-08-06
IL284015A (en) 2021-08-31
DK3890740T3 (da) 2023-05-08
ZA202103044B (en) 2026-05-27
EP4218761A1 (en) 2023-08-02
LT3890740T (lt) 2023-03-27
JP7565921B2 (ja) 2024-10-11
IL284015B1 (en) 2024-06-01
EP3890740B1 (en) 2023-03-01
CN115920034B (zh) 2026-01-02
UY38511A (es) 2020-07-31

Similar Documents

Publication Publication Date Title
JP7565921B2 (ja) 急性骨髄性白血病の治療のための、ｃｄ７０及びベネトクラクス、ｂｃｌ－２阻害剤、組合せ療法
KR102799514B1 (ko) 급성 골수성 백혈병(acute myeloid leukaemia) 치료를 위한 항 cd70-항체 argx-110의 용도
US20240182590A1 (en) Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor
CA3117282C (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
KR20250175330A (ko) 항체-약물 콘주게이트와 다른 약제의 조합
HK40097470A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40091007B (en) Cd70 and a bcl-2 inhibitor combination therapy for treating acute myeloid leukemia
HK40091007A (zh) 用於治疗急性骨髓性白血病的cd70 和bcl-2 抑制剂的组合疗法
HK40052961B (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40052961A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
EA049354B1 (ru) Cd70 и венетоклакс, ингибитор bcl-2, комбинированная терапия для лечения острого миелоидного лейкоза
HK40049607A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40049607B (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40089820A (en) Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor
US20250195653A1 (en) Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders
EA050897B1 (ru) Способ лечения пациентов с пониженной чувствительностью к ингибитору bcl-2